Study of rusfertide for polycythemia vera in China
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational drug called rusfertide for people with polycythemia vera whose red blood cell levels are not well controlled. It aims to see if rusfertide can help manage your condition without needing as many phlebotomies (blood removal procedures).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and live in China.
- You have been diagnosed with polycythemia vera (PV) using updated medical criteria.
- Your red blood cell levels (hematocrit) have been high (45% or above) at least 3 times in the past 28 weeks or at least 5 times in the past year.
- You have had a high hematocrit reading (45% or above) within the last 3 months.
- You are willing to use effective birth control if you or your partner could become pregnant.
- You have not had a major bleeding event or blood clot in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called rusfertide for polycythemia vera (PV)—a blood condition where your body makes too many red blood cells. The trial aims to see if rusfertide can help reduce the need for blood removal procedures (phlebotomy) that PV patients currently need to manage their condition.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.